Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450827 · ClinicalTrials.gov registry record · Phase 1
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00450827: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00450827 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00450827, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8 and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of neuroblastoma by blocking blood flow to the tumor. Giving iodine I 131 monoclonal antibody 3F8 together with bevacizumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of iodine I 131 monoclonal antibody 3F8 when given together with bevacizumab in treating patients with relapsed or refractory neuroblastoma.
Interventions
- PROCEDURE autologous hematopoietic stem cell transplantation
- BIOLOGICAL bevacizumab
- BIOLOGICAL filgrastim
- RADIATION iodine I 131 monoclonal antibody 3F8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-08 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450827
The ClinicalTrials.gov registry entry for NCT00450827 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which autologous hematopoietic stem cell transplantation is the first listed.
NCT00450827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450827 about?
NCT00450827 is a clinical study titled "Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma". RATIONALE: Monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8 and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may al...
What is the current status of trial NCT00450827?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-08. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00450827?
The interventions under investigation include: autologous hematopoietic stem cell transplantation (PROCEDURE), bevacizumab (BIOLOGICAL), filgrastim (BIOLOGICAL), iodine I 131 monoclonal antibody 3F8 (RADIATION).
Who is sponsoring clinical trial NCT00450827?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.